12:00 AM
 | 
Dec 16, 2013
 |  BC Week In Review  |  Company News  |  Deals

Flag Therapeutics, Duquesne University deal

Flag acquired exclusive, worldwide rights to anti-antiogenic/anti- tubulin compounds and folate-targeted anti-cancer compounds developed at the university. The agreement includes...

Read the full 81 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >